Get the Stockscreener App
7.70
2.53%
0.19
Pre-market:
7.73
0.03
+0.39%
Cns Pharmaceuticals Inc stock is traded at $7.70, with a volume of 9,549.
It is up +2.53% in the last 24 hours and down -14.44% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$7.51
Open:
$7.32
24h Volume:
9,549
Relative Volume:
0.20
Market Cap:
$4.42M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.1089
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-6.69%
1M Performance:
-14.44%
6M Performance:
-40.86%
1Y Performance:
-88.50%
1-Day Range:
$7.2619
$7.75
1-Week Range:
$7.2619
$8.65
52-Week Range:
$4.93
$114.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
7.70 | 4.32M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Will CNS Pharmaceuticals Inc. stock recover faster than peersWeekly Trade Recap & Reliable Breakout Stock Forecasts - newser.com
Will CNS Pharmaceuticals Inc. stock return to pre crisis levels2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Can CNS Pharmaceuticals Inc. hit a new high this monthJuly 2025 Breakouts & Expert-Curated Trade Recommendations - newser.com
Will CNS Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Is CNS Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Institutional & Weekly High Potential Stock Alerts - newser.com
Custom watchlist performance reports with CNS Pharmaceuticals Inc.Stop Loss & Stepwise Swing Trade Plans - newser.com
Trend analysis for CNS Pharmaceuticals Inc. this week2025 Top Gainers & Weekly High Return Stock Forecasts - newser.com
Will CNS Pharmaceuticals Inc. stock recover after recent drop2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Is CNS Pharmaceuticals Inc. stock reversal real or fake2025 Stock Rankings & AI Forecasted Stock Moves - newser.com
Using Ichimoku Cloud for CNS Pharmaceuticals Inc. technicalsPortfolio Profit Report & AI Based Buy/Sell Signal Reports - newser.com
Will CNS Pharmaceuticals Inc. stock continue upward momentumPortfolio Performance Summary & Accurate Intraday Trading Signals - fcp.pa.gov.br
How CNS Pharmaceuticals Inc. stock reacts to job market dataJuly 2025 Institutional & Verified Technical Trade Signals - fcp.pa.gov.br
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):